Elicio Therapeutics, Inc. Common Stock

ELTXNASDAQ • USD
1.50 USD
↘ 0.01 (0.33%)🟢LIVE (AS OF 02:58 PM EST)
🟢Market: OPEN

ELTX is currently priced at $1.50. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Nov 13, 2026.

Open?$1.52
High?$1.58
Low?$1.44
Prev. Close?$1.50
Volume?131.0K
Avg. Volume?302.7K
VWAP?$1.49
Rel. Volume?0.43x
Bid / Ask
Bid?$1.50 × 100
Ask?$1.51 × 200
Spread?$0.01
Midpoint?$1.51
Valuation & Ratios
Market Cap?42.5M
Shares Out?28.3M
Float?19.0M
Float %?72.2%
P/E Ratio?N/A
P/B Ratio?2.25
EPS?-$1.26
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Employees
33
Market Cap
42.5M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2023-06-02
Address
451 D STREET, 5TH FLOOR
BOSTON, MA 02210
Phone: (857) 209-0050
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
65
Short Sent.?
55
Piotroski F-Score?0/9Weak
Altman Z-Score?-10.49Distress
Confidence?49%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?9.67%Elevated
Short Interest?1.8M
Days to Cover?5.9
Free Float19.0M
Avg Daily Volume313.1K
Settlement Date2026-10-30
Financial Health
Current Ratio?3.43Strong
Quick Ratio?3.43Strong
Cash Ratio?3.11Strong
Debt/Equity?0.51Moderate
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
69
2.25CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.6CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-189.6%WEAK▾
ROA?
S&P
3
-90.3%WEAK▾
Cash Flow & Enterprise
FCF?$-36987000
Enterprise Value?$21.2M
Fundamentals ratios updated end of day